Personalized Explanations for Early Diagnosis of Alzheimer’s Disease Using Explainable Graph Neural Networks with Population Graphs
Year: 2023
Type: article
Abstract: Leveraging recent advances in graph neural networks, our study introduces an application of graph convolutional networks (GCNs) within a correlation-based population graph, aiming to enhance Alzheimer's disease (AD) prognosis and illuminate the intricacies of AD progression. This methodological approach leverages the inherent structure and correlations in demographic and neuroimaging data to predict amyloid-beta (Aβ) positivity. To validate our approach, we conducted extensive performance comparisons with conventional machine learning models and a GCN model with randomly assigned edges. The results consistently highlighted the superior performance of the correlation-based GCN model across different sample groups in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, suggesting the importance of accurately reflecting the correlation structure in population graphs for effective pattern recognition and accurate prediction. Furthermore, our exploration of the model's decision-making process using GNNExplainer identified unique sets of biomarkers indicative of Aβ positivity in different groups, shedding light on the heterogeneity of AD progression. This study underscores the potential of our proposed approach for more nuanced AD prognoses, potentially informing more personalized and precise therapeutic strategies. Future research can extend these findings by integrating diverse data sources, employing longitudinal data, and refining the interpretability of the model, which potentially has broad applicability to other complex diseases.
Source: Bioengineering
Author: So Yeon Kim
Institution: Ajou University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,224
Funders: U.S. Department of Defense, Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Roche, Biogen, University of Southern California, Meso Scale Diagnostics, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, National Research Foundation, National Research Foundation of Korea, Eisai, Servier, H. Lundbeck A/S, Ministry of Science and ICT, South Korea, National Institutes of Health, Genentech, Canadian Institutes of Health Research, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
Awards: G1012222616, G1991702869, G2522063444, G3146424788, G3255624954, G3870774570, G3966393351, G4119534169, G4196769506, G4401988282, G4475667458, EFFECTS OF TRAUMATIC BRAIN INJURY (TBI) AND POST TRAUMATIC STRESS DISORDER (PTSD) ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING IMAGING AND BIOMARKERS IN THE AD NEUROIMAGING INITIATIVE (ADNI)", Alzheimer's Disease Neuroimaging Initiative, G5752754369, G8629272432, G9000074849, G9000122335, G920654007
OpenAlex ID: W4380052386
